News

Sanofi to buy US blood disorder drugmaker for up to $9.5bn
Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.
Clinical Trials Arena1h
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
STAT3d
Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials
An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...
The Business Times1h
Sanofi to buy immunology biotech Blueprint for US$9.1 billion
PARIS] Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare ...
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...
CNBCTV183h
US Stock Market Live: Dow futures down 150 points; Sanofi to make $9.1 billion acquisition
Futures on Wall Street have begun trading on Sunday evening US time on a negative note amidst rising uncertainties on trade ...